Eli Lilly & Company (LLY) Poised for Bullish Momentum with Positive Fundamentals and Technicals

Fundamental Analysis

Eli Lilly and Company (LLY) has shown positive dynamics as the EPS is at $7.17, which is a good sign of company profitability. With a PE of 81.79, it indicates that the investors are ready to pay a high price for each dollar of earnings, revealing bullish market sentiment.

The company has a substantial market cap, valued at $556.72 billion, which positions it as a large-cap reputable stock in the market. There are currently approximately 949.29 million shares outstanding.

The latest news suggests potential growth avenues for the LLY stock. The increasing economic cost of obesity, that is expected to reach $4 trillion by 2035, opens avenues for obesity and weight loss drug manufacturers like Eli Lilly. The company's drug, Mounjaro, has also recently received backing from Britain's drug cost-effectiveness watchdog, which further enhances its standing in the global diabetes treatment market.

Analyst consensus points towards 'Buy' with 14 buy ratings; no hold, sell or strong sell ratings at stood at the date of last close. This suggests analysts are bullish on the company's future growth and expect its shares to rise further.

The Discounted Cash Flow (DCF) value is $588.74, which is above its last close price of $586.46. This indicates the stock is undervalued according to the DCF model, suggesting potential for upward movement.

Technical Analysis

Looking at key insights from the price data, Eli Lilly and Company has displayed robust upward momentum in recent times. Its last close was at $586.46, with a positive change of $13.23 (2.31%). The stock has made a dramatic journey from its 52-week low of $296.32 to its 52-week high of $587.55.

The high trading volume of 4.3 million compared to the average volume of 2.77 million signifies increased investor interest and trading activity in LLY.

The company's RSI14 stands at 82, which places the stock in an overbought zone risking a potential pullback. The company's 50-day moving average ($495.16) and 200-day moving average ($404.33), both are way lower than the current price, signaling a strong uptrend.

From a MACD perspective, a 3-month MACD of 31.55 is a positive signal and indicates underlying bullish sentiment.

In terms of ATR, LLY's stands at 1.90. This low value indicates that the stock has low volatility.

Currently, there are no defined resistance levels for LLY, suggesting potential for further price appreciation. The stop loss for the stock is at $566.75, and support level is at $526.23.

Stock Prediction

For the next trading day on September 11, 2023, considering the fundamental factors, technical indicators, and recent news, LLY might witness a bullish momentum. However, traders need to be cautious due to the high RSI value and potential for a pullback.

For the upcoming week, given the company's strong fundamental outlook, positive news, and technical bullish trend, the stock price is expected to rise, barring any major unpredictable market or sector changes.

Final Evaluation

Evaluated based on the fundamental and technical aspects, Eli Lilly and Company (LLY) is categorised as a 'Buy'. This is based on its optimistic future growth prospects, substantial market capitalisation, robust financial indicators, trending bullish sentiment, potential in the rising economic cost of obesity, and recent backing for its diabetes drug, Mounjaro.

However, investors should keep a close eye on the overbought RSI signals and consider stop-loss orders to protect their positions from potential downside risk.